A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.

Cancer Med · 2023 · PMC10726920 · PMID 37960985

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a trend toward significancep = 0.08so close (0.05 < p ≤ 0.1)

However, patients displayed a correlation between systemic sapanisertib exposure and non‐hematologic AEs on Cycle 1 Day 1 ( p = 0.03) and a trend toward significance on Day 8 ( p = 0.08). 3.4.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.